News Focus
News Focus
icon url

samk

08/01/25 11:30 AM

#495844 RE: Hoskuld #495841

Thank you, Hoskuld! This is great rebuttal to Doc's and Investor's bashing..
icon url

boi568

08/01/25 12:28 PM

#495864 RE: Hoskuld #495841

Where are you getting the 85 percent slowing figure from?
icon url

powerwalker

08/01/25 12:55 PM

#495872 RE: Hoskuld #495841

So, work your way back and you can see that roughly 83% of all the benefit was experienced by 35% of the total.



If I recall, there were 33-34% of the participants who were DPZ-naïve.


ANAVEX NOW ... MONO-STYLE!!!
Bullish
Bullish
icon url

tschussmann1

08/05/25 7:53 PM

#496410 RE: Hoskuld #495841

A thought that I just had, but I expect Anavex has had for a while: can a precision drug be designed for each of the 4 genetic combinations, so that each group would be super responders for one drug. Assuming Blarcamesine is that for Sigmar1 Wild Type and COL24A1 Base, need 3 more drugs for the other 3 genetic combinations. Not sure if that is a "tweak" of Blarcamesine, or design from scratch. If Anavex could patent this space, that would be monumental.